Kifa Therapeutics advances highly selective CNS-kinase inhibitors, starting with a G2019S-LRRK2 therapy for Parkinson’s disease.
Our strategy pairs genetics-based patient selection with validated biomarkers to enable efficient clinical studies and an orphan, accelerated-approval path.
SelSym Biotech is pioneering hemostasis with SymClot, an innovative platelet-mimetic therapy that promises to dramatically improve patient survival and outcomes by rapidly stopping bleeding after severe trauma and high-risk surgeries.
Moonlight Therapeutics is a clinical-stage biotech company developing MOON101, a novel microneedle stamp treatment for peanut allergy that delivers allergen proteins directly into the skin to safely desensitize the immune system.
At Myosin Therapeutics, we’re tackling aggressive, treatment-resistant cancers by targeting a completely new frontier in cancer biology—the molecular nanomotors that power cancer cell movement, invasion, and survival.
PHIOGEN is a pre-clinical-stage biotechnology company developing first-in-class immunizing therapeutics designed to both treat drug-resistant infections and induce durable immune protection against recurrence, with a focus on chronic conditions.
